BINOSTO is the first and only prescription medicine for the treatment of osteoporosis in postmenopausal women and treatment to increase bone mass in men with osteoporosis that gives you proven fracture protection in a buffered, effervescent solution. It is a treatment option when tablets just aren't the right choice--for any reason.
Important Limitations of Use: Optimal duration of use has not been determined. The safety and effectiveness of BINOSTO for the treatment of osteoporosis are based on clinical data of four years duration. All patients on bisphosphonate therapy should have the need for continued therapy re-evaluated on a periodic basis.
Alendronate sodium has helped treat osteoporosis in postmenopausal women since 1995. For many years, it has been prescribed by doctors to build bone and protect from fractures at the hip and spine.
Fosamax® was the branded alendronate sodium approved by the US Food and Drug Administration (FDA) as being safe and effective. Generic alendronate sodium products became available to patients over time with the same alendronate sodium to help prevent and treat osteoporosis. Both Fosamax and the generic versions of the drug are available in a tablet that must be taken with 8 oz of water. Other conditions of use apply.
BINOSTO, once dissolved in 4 oz of water, forms a buffered effervescent solution. It is taken once weekly. The FDA approved BINOSTO and found it to be bioequivalent to Fosamax1, which means it works the same way.
BINOSTO is not a tablet that you swallow whole. It is an effervescent tablet that dissolves completely in water to become a strawberry-flavored, buffered solution.